Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference
Presentation moved to 1:20 p.m. GMT (8:20 a.m. ET) on November 20, 2019 BOSTON , Nov. 18, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that the Company’s presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , has been moved to 1:20
View HTML
Toggle Summary Ziopharm Oncology Presentation at the Jefferies 2019 London Healthcare Conference to be Webcast
BOSTON , Nov. 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to make a webcast presentation at the Jefferies 2019 London Healthcare Conference on November 20, 2019 , beginning
View HTML
Toggle Summary Ziopharm Oncology Reports Third Quarter 2019 Financial Results
– Phase 2 trial of Sleeping Beauty TCR-T cell therapy for  patients with solid tumors initiated at the National Cancer Institute (NCI) – – New agreement with MD Anderson Cancer Center to expand library of T-cell receptors (TCRs) targeting neoantigens; Enables new clinical trials – – Balance sheet
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call to Discuss Third Quarter 2019 Results on November 7, 2019
BOSTON , Oct. 30, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Thursday, November 7 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the third quarter ended September 30 ,
View HTML
Toggle Summary Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
–  Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots –              – Enables two new TCR-T clinical trials at MD Anderson leveraging the Sleeping Beauty non-viral gene transfer platform – – New lease for larger facility allows
View HTML
Toggle Summary Ziopharm Oncology Names Drug Development Leader Dr. Chris Bowden to Board of Directors
– Industry veteran with 20+ years of global oncology drug development leadership –   – Current CMO at Agios Pharmaceuticals ; Former VP of Product Development, Oncology at Genentech –   BOSTON , Oct. 15, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP),
View HTML
Toggle Summary Ziopharm Oncology Announces FDA Clearance of IND for Rapid Personalized Manufacture of CD19-specific CAR-T
– Phase 1   clinical trial of CAR-T produced and infused in two days or less from gene transfer using Ziopharm’s Sleeping Beauty platform –   – Rapid personalized manufacture of CD19-specific CAR-T  for investigation in unaddressed patient population with relapsed leukemias and lymphoma after bone
View HTML
Toggle Summary Ziopharm Oncology to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference
BOSTON , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP) today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, will participate in a webcast fireside chat at the Morgan Stanley 17 th Annual Global Healthcare Conference in New York on
View HTML
Toggle Summary Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BOSTON , Aug. 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP) today reported that the Company granted a new employee an option to purchase an aggregate of 65,000 shares of Ziopharm’s common stock effective August 19, 2019 .
View HTML
Toggle Summary Ziopharm Oncology Announces Publication of Positive Results of Phase 1 Monotherapy Trial of Controlled IL-12 in Patients with Recurrent Glioblastoma in Science Translational Medicine
– Ad-RTS-hIL-12 plus 20 mg veledimex (Controlled IL-12 platform) determined to be the preferred dose with low-dose steroids to treat adult patients with recurrent glioblastoma – – Median overall survival for Controlled IL-12 in patients receiving low-dose steroids was 17.8 months – – Increased
View HTML